No profile data available.
Achieve Life Sciences, Inc. (ACHV) is a healthcare company in the poison treatment pharmaceuticals industry, based in Bothell, United States, with about 28 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$54.65 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $763.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Achieve Life Sciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$763.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Indivior PLC (INDV), Aquestive Therapeutics, Inc. (AQST), Fennec Pharmaceuticals Inc. (FENC), Anebulo Pharmaceuticals, Inc. (ANEB).